In vivo, DGKi combined with PD-1 blockade slowed tumor growth in settings where PD-1 blockade alone was ineffective, suggesting that DGKi could expand the range of patients who could benefit from PD-1/PD-L1 blockade. This evidence concerns the gene PDCD1 and neoplasm.